Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). Bladder dysfunction is a common consequence of MS. The prevalence and severity of bladder dysfunction increase depending the severity of MS. Due to the fact that several components of the CNS are associated with regulating urination, thus MS may lead to a wide range of urinary symptoms and urologic complications. Although lower urinary tract symptoms (LUTS) are not a major cause of mortality, they are highly prevalent chronic conditions which negatively affect health-related quality of life (HRQOL). Due to the chronic and non-fatal nature of LUTS, most patients have to learn to live with their urinary problems. Therefore, improving HRQOL are often the key goals of most LUTS intervention. LUTS are associated with high personal and societal costs, both in direct medical costs and indirect losses in daily functioning. The substantial impact of LUTS on QoL reinforces the need for their treatment, and indicates the potential benefits of effective intervention. In addition, treatment of LUTS has been shown to improve QoL.